Algorithm for the Management of Osteoporosis

Southern Medical Journal

Volumn 103, Issue 10, 2010, Pages 1009-1017

  Hamdy, Ronald C ^a   Baim, Sanford ^b   Broy, Susan B ^b   Lewiecki, E Michael ^b   Morgan, Sarah L ^b   Tanner, S Bobo ^b   Williamson, Howard F ^b  

^a East Tennessee State University   (United States)

^b NONE

Author keywords

Algorithm; FRAX; Osteopenia; Osteoporosis; Vitamin D

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALENDRONIC ACID; AROMATASE INHIBITOR; CALCITONIN; CALCIUM; DENOSUMAB; GLUCOCORTICOID; HEPARIN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PHENOBARBITAL; PHENYTOIN; PREDNISONE; PROTON PUMP INHIBITOR; RALOXIFENE; RETINOL; RISEDRONIC ACID; SEROTONIN UPTAKE INHIBITOR; VITAMIN D; ZOLEDRONIC ACID;

ALGORITHM; BONE DENSITY; BONE MASS; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; MONITORING; OSTEOPOROSIS; PATIENT CARE; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; AGE; AGED; ARTICLE; CLINICAL PROTOCOL; EXERCISE; FEMALE; FRACTURE; MALE; MIDDLE AGED; RISK FACTOR;

AGE FACTORS; AGED; ALGORITHMS; BONE DENSITY; CLINICAL PROTOCOLS; EXERCISE; FEMALE; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS; VITAMIN D;

EID: 77958134940     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181f0e8d6     Document Type: Review

References (39)

1. Consensus Development Conference 1991: prophylaxis and treatment of osteoporosis. Am J Med 1991;90:107-110.
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-795.
3. Bürge RT, Dawson-Hughes B, Solomon D, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-475.
4. Riggs BL, Melton LJ III. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17(5 suppl):505S-511S.
5. American Heart Association and American Stroke Association. Heart Disease and Stroke Statistics: 2007 Update at-a-Glance. Dallas, American Heart Association, 2007. Available at: http://www.americanheart.org/downloadable/ heart/1166712318459HS-StatsInsideText.pdf. Accessed April 27, 2010.
6. American Cancer Society. Cancer Facts and Figures 2009. Atlanta, American Cancer Society. 2009. Available at: http://www.cancer.org/downloads/STT/ 500809web.pdf. Accessed April 27, 2010.
7. Hooven F, Gehlbach SH, Pekow P, et al. Follow-up treatment for osteoporosis after fracture. Osteoporosis Int 2005;16:296-301.
8. Siris ES, Bilezikian JP, Rubin MR, et al. Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab 2003;88:3482-3486.
9. Castel H, Bonneh DY, Sherf M, et al. Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures. Osteoporosis Int 2001;12:559-564.
10. Gold DT, Silverman SL. Compliance with osteoporosis medications: challenges for healthcare providers. Medscape Ob/Gyn Womens Health. 2005. Available at: www.medscape.com/viewarticle/503214. Accessed September 26, 2006.
11. Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med 2006;119(4 suppl 1):S3-S11.
12. Edwards BJ, Bunta AD, Madison LD, et al. An osteoporosis and fracture intervention program increases the diagnosis and treatment for osteoporosis for patients with minimal trauma fractures. Jt Comm J Qual Patient Saf 2005;31:267-274.
13. Stafford RS, Drieling RL, Johns R, et al. National patterns of calcium use in osteoporosis in the United States. J Reprod Med 2005;50(suppl 11):885-890.
14. Ott S. Osteoporosis and Bone Physiology. Available at: http://courses. washington.edu/bonephys/. Updated July 2, 2007. Accessed February 18, 2010.
15. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, U.S. Department of Health and Human Services, Office of the Surgeon General, 2004.
16. Elliot-Gibson V, Bogoch ER, Jamal SA, et al. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 2004;15:767-778.
17. Jennings LA, Auerbach AD, Maselli J, et al. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. JAm Geriatr Soc 2010;58:650-657.
18. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC, National Osteoporosis Foundation, 2008. Available at: www.nof.org/physguide. Accessed February 18, 2010.
19. International Society for Clinical Densitometry. 2007 Official Positions and Official Pediatric Positions. Availableat:http://www.iscd.org/Visitors/pdfs/ ISCD2007OfficialPositions-Combined-AdultandPediatric.pdf. Accessed February 7, 2010.
20. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause 2006;13:340-367.
21. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002;137:526-528.
22. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001;44:1496-1503.
23. Centers for Medicare and Medicaid Services. Medicare preventive services: bone mass measurements. Available at: http://www.cms.gov/MLNProducts/downloads/ bone-mass.pdf. Department of Health and Human Services. Updated July 2009. Accessed April 26, 2010.
24. Cazzaniga ME, Mustacchi G, Pronzato P, et al; NORA Study Group. Adjuvant systemic treatment of early breast cancer: the NORA study. Ann Oncol 2006;17:1386-1392.
25. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19: 385-397.
26. Cummings SR, Black DM, Thompson DE. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082.
27. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-1352.
28. McClung MR, Geusens P, Miller PD, et al; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344:333-340.
29. Chesnut CH, Skag A, Christiansen C, et al; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19: 1241-1249.
30. Black DM, Delmas PD, Eastell R, et al; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822.
31. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-645.
32. Chesnut CH III, Silverman S, Adriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. Am J Med 2000;109:330-331.
33. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441.
34. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New Engl J Med 2009;361:756-765.
35. Sinaki M. Critical appraisal of physical rehabilitation measures after osteoporotic vertebral fracture. Osteoporos Int 2003;14:773-779; Erratum in: Osteoporos Int 2006;17:1702.
36. Heaney RP. The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 2005;97:13-19.
37. Garnero P, Delmas PD. Biochemical markers of bone turnover in osteoporosis, in Marcus M, Feldman D, Kelsey J (eds): Osteoporosis San Diego, Academic Press, 2001, vol 2, ed 2, pp 459-477.
38. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-1022.
39. Ettinger MP, Gallagher R, Amonkar M. Medication persistence is improved with less frequent dosing of bisphosphonates but remains inadequate. Arthritis Rheum 2004;50(suppl):S513-S514. [Abstract 1325].